Last C$0.11 CAD
Change Today +0.005 / 5.00%
Volume 110.6K
CUR On Other Exchanges
Symbol
Exchange
Toronto
OTC US
As of 3:52 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

diagnocure inc (CUR) Snapshot

Open
C$0.10
Previous Close
C$0.10
Day High
C$0.11
Day Low
C$0.10
52 Week High
01/14/14 - C$0.24
52 Week Low
10/16/14 - C$0.10
Market Cap
4.5M
Average Volume 10 Days
57.3K
EPS TTM
C$-0.05
Shares Outstanding
43.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAGNOCURE INC (CUR)

Related News

No related news articles were found.

diagnocure inc (CUR) Related Businessweek News

No Related Businessweek News Found

diagnocure inc (CUR) Details

DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and GCC marker, Previstage GCC staging test, GCC monitoring blood test, Shc proteins, and scientific publications for use in colorectal cancer management. The company was founded in 1994 and is headquartered in Quebec, Canada.

11 Employees
Last Reported Date: 01/27/14
Founded in 1994

diagnocure inc (CUR) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: C$180.1K
Interim Chief Financial Officer and Senior Di...
Total Annual Compensation: C$129.7K
Compensation as of Fiscal Year 2013.

diagnocure inc (CUR) Key Developments

DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014

DiagnoCure Inc. reported consolidated earnings results for the third quarter ended July 31, 2014. For the quarter, the company reported total revenues of $153,424 against $189,585 a year ago. This decrease of $36,161 or 19% is mostly attributable to PCA3 royalties, reflecting a decrease in U.S. royalty revenues. Net loss (before stock-based compensation, depreciation and amortization) was $406,853 against $351,753 a year ago. Net loss and comprehensive loss was $504,105 against $595,262 a year ago. Basic and diluted net loss per share was $0.01 against $0.01 a year ago.

DiagnoCure Inc. Announces Earnings Results for the Six Months Ended April 30, 2014

DiagnoCure Inc. announced earnings results for the six months ended April 30, 2014. For the period, the company reported net loss and comprehensive loss for the six months ended April 30, 2014 was CAD 1.07 million, or CAD 0.02 loss per share, compared to a net loss of CAD 1.64 million, or CAD 0.04 loss per share, for the same period ended April 30, 2013. Total revenues for the six months ended April 30, 2014 were CAD 277,462, compared to CAD 332,178 for the same period ended April 30, 2013.

DiagnoCure Inc. Announces Earnings Results for the Second Quarter Ended April 30, 2014

DiagnoCure Inc. announced earnings results for the second quarter ended April 30, 2014. For the quarter, the company reported license and royalty revenues of $130,493 compared to $164,262 a year ago. Total revenues were $130,493 compared to $164,262 a year ago. Net loss (before stock-based compensation, depreciation and amortization) was $431,706 compared to $609,780 a year ago. Net loss and comprehensive loss was $536,597 or $0.01 per basic and diluted share compared to $849,344 or $0.02 per basic and diluted share a year ago. The decrease in revenue was $33,769 or 21% is attributable to PCA3 royalties, reflecting a reduction of 32% in U.S. royalty revenues and an increase of 1% in European royalty revenues as compared to the same period in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:CN C$0.11 CAD +0.005

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CUR.
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAGNOCURE INC, please visit www.diagnocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.